2.11%
6.14%
23.47%
21.00%
19.80%
-56.08%
-44.24%
AI Spotlight on STXS
Company Description
Stereotaxis, Inc.designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room.In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters.Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components.
Stereotaxis, Inc.markets its products through direct sales force, distributors, and sales agents.The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology.
Stereotaxis, Inc.was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Market Data
| Last Price | 2.42 |
| Change Percentage | 2.11% |
| Open | 2.38 |
| Previous Close | 2.37 |
| Market Cap ( Millions) | 205 |
| Volume | 591537 |
| Year High | 3.29 |
| Year Low | 1.66 |
| M A 50 | 2.23 |
| M A 200 | 2.09 |
Financial Ratios
| FCF Yield | -5.97% |
| Dividend Yield | 0.00% |
| ROE | -115.14% |
| Debt / Equity | 37.82% |
| Net Debt / EBIDTA | 21.04% |
| Price To Book | 12.8 |
| Price Earnings Ratio | -9.63 |
| Price To FCF | -16.76 |
| Price To sales | 8.16 |
| EV / EBITDA | -9.32 |
News
- Jan -30 - Stereotaxis Announces First GenesisX Robotic System Order
- Jan -27 - Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
- Jan -14 - Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
- Dec -16 - STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
- Dec -09 - Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
- Dec -02 - Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
- Dec -02 - Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
- Nov -26 - STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
- Nov -26 - Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
- Nov -25 - Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
- Nov -20 - Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
- Nov -12 - Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
- Nov -11 - Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates
- Nov -11 - Stereotaxis Reports 2024 Third Quarter Financial Results
- Oct -21 - Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
- Sep -09 - Stereotaxis to Present at Upcoming Investor Conferences
- Sep -03 - Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress
- Aug -25 - Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval
- Aug -15 - Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
- Aug -15 - Stereotaxis (STXS) Receives European Approval for GenesisX
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Disposables, Service and Accessories
Expected Growth : 8.37 %
What the company do ?
Disposables, Service, and Accessories from Stereotaxis, Inc. refer to medical devices and tools used in cardiac ablation procedures, including catheters, introducers, and navigation systems.
Why we expect these perspectives ?
Stereotaxis, Inc.'s 8.37% growth in Disposables, Service, and Accessories is driven by increasing adoption of robotic navigation in electrophysiology procedures, growing demand for minimally invasive treatments, and expansion into new geographies. Additionally, the company's focus on innovation, customer support, and strategic partnerships contributes to its growth momentum.
Segment n°2 -> Systems
Expected Growth : 8.9 %
What the company do ?
Stereotaxis, Inc. offers advanced robotic systems for minimally invasive cardiac interventions, enabling precise navigation and enhanced patient care.
Why we expect these perspectives ?
Stereotaxis, Inc.'s 8.9% growth is driven by increasing adoption of robotic navigation systems in electrophysiology, rising demand for minimally invasive procedures, and expanding presence in emerging markets. Additionally, strategic partnerships, innovative product offerings, and growing physician acceptance of robotic-assisted ablation procedures contribute to the company's growth momentum.
Stereotaxis, Inc. Products
| Product Range | What is it ? |
|---|---|
| Niobe ES System | A magnetic navigation system for cardiac ablation procedures, providing precise and stable catheter navigation. |
| Quarteto RF Ablation System | A radiofrequency ablation system for cardiac ablation procedures, providing precise and controlled energy delivery. |
| Vdrive Duo | A remote catheter navigation system for cardiac ablation procedures, providing precise and stable catheter navigation. |
| Odyssey Solution | A data management and analytics platform for electrophysiology labs, providing insights and workflow optimization. |
Stereotaxis, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Stereotaxis, Inc. is moderate due to the presence of alternative medical technologies and treatments.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of Stereotaxis' products and services, which limits customer negotiating power.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers for Stereotaxis' components and materials.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the medical technology industry, including regulatory hurdles and significant capital requirements.
Intensity Of Rivalry
The intensity of rivalry is high due to the competitive nature of the medical technology industry, with multiple established players competing for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 20.03% |
| Debt Cost | 3.95% |
| Equity Weight | 79.97% |
| Equity Cost | 10.69% |
| WACC | 9.34% |
| Leverage | 25.05% |
Stereotaxis, Inc. : Quality Control
Stereotaxis, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| EKSO | Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, … |
| SMTI | Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen … |
| ANGO | AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use … |
| RVP | Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and … |
| BLFS | BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Retractable Technologies
A-Score
1-Year Total Return ->
🥈
BioLife Solutions
A-Score
1-Year Total Return ->
🥉
Stereotaxis
A-Score
1-Year Total Return ->
4
Sanara MedTech
A-Score
1-Year Total Return ->
5
AngioDynamics
A-Score
1-Year Total Return ->
6
